PHASE II STUDY OF ADI-PEG 20 IN PATIENTS WITH RELAPSED SENSITIVE OR REFRACTORY SMALL CELL LUNG CANCER
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Pegargiminase (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 10 May 2017 Status changed from active, no longer recruiting to discontinued.
- 25 Oct 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 25 Oct 2012 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.